PE20141381A1 - Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer - Google Patents

Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer

Info

Publication number
PE20141381A1
PE20141381A1 PE2013002911A PE2013002911A PE20141381A1 PE 20141381 A1 PE20141381 A1 PE 20141381A1 PE 2013002911 A PE2013002911 A PE 2013002911A PE 2013002911 A PE2013002911 A PE 2013002911A PE 20141381 A1 PE20141381 A1 PE 20141381A1
Authority
PE
Peru
Prior art keywords
inhibitor
cancer
cdk4
treatment
combination therapy
Prior art date
Application number
PE2013002911A
Other languages
English (en)
Inventor
Sunkyu Kim
Shivang Doshi
Kristy Haas
Steven Kovats
Alan Xizhong Huang
Yan Chen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46513871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141381(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20141381A1 publication Critical patent/PE20141381A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMBINACION QUE COMPRENDE: A) UN PRIMER AGENTE QUE ES UN INHIBIDOR DE CINASA 4 DEPENDIENTE DE CICLINA O CINASA 6 DEPENDIENTE DE CICLINA (CDK4/6) Y B) UN SEGUNDO AGENTE QUE ES UN INHIBIDOR DE PI3CINASA. DICHA COMBINACION ES UTIL PARA EL TRATAMIENTO DE CANCER DE MAMA, SARCOMAS, CANCER GASTRICO, MELANOMA, LEUCEMIA, CANCER DE PROSTATA
PE2013002911A 2011-07-01 2012-07-02 Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer PE20141381A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161503642P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
PE20141381A1 true PE20141381A1 (es) 2014-10-21

Family

ID=46513871

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002911A PE20141381A1 (es) 2011-07-01 2012-07-02 Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer

Country Status (23)

Country Link
US (2) US9271988B2 (es)
EP (1) EP2726074B1 (es)
JP (2) JP5832647B2 (es)
KR (1) KR20140040770A (es)
CN (1) CN103635189B (es)
AU (3) AU2012279117A1 (es)
BR (1) BR112013033940A2 (es)
CA (1) CA2840754A1 (es)
CL (1) CL2013003805A1 (es)
CO (1) CO6842016A2 (es)
EA (1) EA030465B1 (es)
ES (1) ES2676180T3 (es)
GT (1) GT201300320A (es)
IL (1) IL229876B (es)
MA (1) MA35210B1 (es)
MX (1) MX359406B (es)
MY (1) MY161237A (es)
PE (1) PE20141381A1 (es)
PH (1) PH12013502697A1 (es)
TN (1) TN2013000508A1 (es)
UA (1) UA114178C2 (es)
WO (1) WO2013006532A1 (es)
ZA (1) ZA201309241B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
EP2726074B1 (en) * 2011-07-01 2018-04-04 Novartis AG Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
MX2014011843A (es) * 2012-03-30 2014-12-10 Novartis Ag Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013296237B2 (en) 2012-08-03 2019-05-16 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
CN105828822B (zh) * 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
AU2016287463B2 (en) 2015-07-02 2020-07-02 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
WO2017037575A1 (en) * 2015-08-28 2017-03-09 Novartis Ag A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
US10690673B2 (en) 2016-03-29 2020-06-23 Mayo Foundation For Medical Education And Research Method of treating cancer metastasis by CDK 4/6 inhibitors
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
KR20190092478A (ko) 2016-12-05 2019-08-07 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
EP3738084A4 (en) 2018-01-08 2021-11-17 G1 Therapeutics, Inc. SUPERIOR G1T38 DOSING SCHEMES
KR20210031852A (ko) * 2018-03-05 2021-03-23 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료
CN111184863B (zh) * 2018-11-15 2023-06-16 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US20240307393A1 (en) * 2021-07-06 2024-09-19 National Cancer Center Pharmaceutical composition for cancer prevention or treatment, comprising cdk4/6 inhibitor and tricyclic antidepressant

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
EA013811B1 (ru) 2002-11-21 2010-08-30 Новартис Вэксинес Энд Дайэгностикс, Инк. 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
PE20091485A1 (es) 2008-02-06 2009-10-26 Novartis Ag DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
SG188439A1 (en) 2010-10-01 2013-05-31 Novartis Ag Manufacturing process for pyrimidine derivatives
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
EP2726074B1 (en) * 2011-07-01 2018-04-04 Novartis AG Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
EP2925365A1 (en) * 2012-11-28 2015-10-07 Novartis AG Combination therapy

Also Published As

Publication number Publication date
EP2726074A1 (en) 2014-05-07
BR112013033940A2 (pt) 2017-02-14
EA201490194A1 (ru) 2014-04-30
ES2676180T3 (es) 2018-07-17
MX2013015370A (es) 2014-02-11
JP5832647B2 (ja) 2015-12-16
JP2014518279A (ja) 2014-07-28
CN103635189B (zh) 2016-05-04
GT201300320A (es) 2016-03-01
AU2016202213A1 (en) 2016-05-05
AU2017232162B2 (en) 2019-03-07
CN103635189A (zh) 2014-03-12
ZA201309241B (en) 2014-08-27
EP2726074B1 (en) 2018-04-04
US20140107114A1 (en) 2014-04-17
JP2016027043A (ja) 2016-02-18
US20160136171A1 (en) 2016-05-19
KR20140040770A (ko) 2014-04-03
AU2017232162A1 (en) 2017-10-12
EA030465B1 (ru) 2018-08-31
CL2013003805A1 (es) 2014-08-08
MA35210B1 (fr) 2014-06-02
TN2013000508A1 (en) 2015-03-30
AU2012279117A1 (en) 2014-01-09
PH12013502697A1 (en) 2014-02-10
IL229876B (en) 2018-10-31
MX359406B (es) 2018-09-27
CO6842016A2 (es) 2014-01-20
US10010552B2 (en) 2018-07-03
US9271988B2 (en) 2016-03-01
WO2013006532A1 (en) 2013-01-10
UA114178C2 (uk) 2017-05-10
MY161237A (en) 2017-04-14
CA2840754A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
PE20141381A1 (es) Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CO6630103A2 (es) Fitocanabinoides en el tratamiento de cáncer
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
AR078824A1 (es) Compuesto de cabazitaxel y sus usos
CR20150368A (es) Inhibidores de histona desmetilasa
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
ECSP099724A (es) Uso de inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cáncer
MX2017013613A (es) Neoepitodos de cancer.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2012000324A1 (es) Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
CL2012000163A1 (es) Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
MX385778B (es) Uso de dianhidrogalactitol y análogos o derivados del mismo para tratar cáncer de células no pequeñas del pulmón y cáncer de ovario.
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CR20140378A (es) Derivados de pirido[2,3-d] pirimidina sustituidos con 2-amino, 6-fenilo útiles como inhibidores de cinasa raf

Legal Events

Date Code Title Description
FG Grant, registration